This milestone, part of the company’s previously announced collaboration with Mercy, marks the world’s first commercial use of Eversense 365, the only CGM to provide one-year of accurate ...

Senseonics shares dipped slightly before hours today on third-quarter results that came in mixed compared to the consensus ...

“An average is not a very good way of measuring what is your control,” he said. “When you have those big excursions of highs ...

The US Food and Drug Administration has cleared Senseonics’ Eversense 365, the latest implantable continuous glucose ...

Eversense 365, the world’s first one-year CGM system, represents a significant breakthrough in diabetes technology and management that is highly differentiated from short-term CGMs. A live ...

Senseonics Holdings (NYSE:SENS), Inc. (NYSE American: SENS), a medical technology company, in collaboration with healthcare provider Mercy, has announced the first commercial patient application of ...

One CGM. Removable transmitter with once a week calibration. We are working hand in hand with Senseonics management to ensure a successful launch of Eversense 365, and we are thrilled to see such ...

Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older ...

About EversenseThe Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense ...